Carlsmed, INC 8-K filings

Carlsmed, Inc. announced robust second quarter 2026 financial results, showcasing 57% year-over-year revenue growth and an increase in gross margins, leading to an upward revision of its full-year revenue outlook.

Carlsmed, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of two Class I directors and the ratification of its independent auditor.

Carlsmed, a medical technology company, announced robust financial results for Q4 and full year 2025, driven by significant revenue growth and gross margin expansion.

Carlsmed, a medical technology company, announced preliminary and unaudited revenue for Q4 2025 and full year 2025, showing significant growth.

Carlsmed, Inc. announced robust third-quarter 2025 financial results, including 98% year-over-year revenue growth, and raised its full-year revenue guidance.

Carlsmed, Inc. has secured a new $50.0 million credit facility from Customers Bank, amending existing loan terms and reducing the number of shares underlying warrants held by the bank.

Carlsmed, Inc. reported a 99% year-over-year revenue increase to $12.1 million in Q2 2025, driven by its AI-enabled aprevo platform, and reaffirmed full-year guidance.

Carlsmed, Inc. has filed its amended corporate charter and bylaws, formalizing governance structures in connection with its recent initial public offering.